YOUR LONG-TERM PARTNER OF CHOICE

    THROUGH INNOVATION IN API DEVELOPMENT

    API Polpharma is a significant European producer of Active Pharmaceutical Ingredients delivering products to pharmaceutical companies worldwide. We are present on 6 continents, in 60+ countries, and our market share is constantly growing. Our well-balanced and expanding portfolio, along with our scientific know-how and experience, allow us to offer attractive solutions for drug developers.

    We provide a one-stop shop solution of vertically integrated services from API development to FDF formulation and manufacturing, scale-up capabilities based on in-house or external custom developed technologies, to regulatory support. DMF documentation for all our products is prepared in accordance with the latest requirements of EDQM (CEP), ICH (ASMF in eCTD format), PMDA (J-DMF) and FDA (US DMF). Our products are manufactured in accordance with the most stringent requirements of our customers and health authorities: USFDA, EMA, EDQM, SKFDA, PMDA, ANVISA, Polish Main Pharmaceutical Inspectorate. Regular FDA audits enabled us to register and sell a number of APIs in the US market and confirm our reliability and credibility towards our business partners around the world.

    OUR VALUES EQUAL
    COMMITMENT TO:

    • Offer a broad based product portfolio and pipeline
    • Offer custom-made synthesis and individual approach to non-standard queries and projects
    • Find innovative solutions to use our APIs in breakthrough finished dosage forms
    • Pioneer non infringing solutions applied in the process development stages, at minimum risk exposure for all of our customers
    • Serve our Client’s best interest at all times
    • Offer competitive prices for our superior quality products and services
    • Foster sustainable development, product stewardship and efficient supply chain
    • Build on science and expertise, state-of-the-art technology, best design processes and practices to deliver attractive solutions for drug development

    what makes us different from other competitors?

    With superior quality of products, customer-centric approach and competitive production costs, API Polpharma is your trustworthy global partner of choice

    • Full scale and vertical integration of processes from R&D,
      GMP Pilot plant, scale-up to manufacturing
    • Highly skilled staff with an ever increasing proportion of university graduates
    • Competitive labor costs and manufacturing site located in the economic zone
    • Wide reaction classes in FDA approved facilities
    • State-of-the-art technology and best design processes and practices
    • Own R&D resources including pilot plant and wide cooperation with external research and academic institutions and laboratories

    kaizen means change for better

    Comprised of highly skilled professionals, our Customer Service Team is committed to helping your business grow in the dynamic pharma environment. We put our customers at the core of what we do. Thus, in our ongoing effort to provide you the highest quality of service, we adopted the Kaizen methodology at the heart of which lies the idea of sustained continual improvement.

    Our service establishes and enhances trust being the foundation of long-term business relations.

    Worldwide presence

    • We are present in 6 continents
    • We supply to 60+ countries
    • Our key export regions are: Europe, Asia and North America
    • We are a trustworthy partner to 300 customers worldwide



    1
    North
    America
    2
    Latam
    3
    Europe
    4
    Mena
    5
    Asia
    6
    Australia

    HISTORY

    1935
     
    1935

    Polpharma is founded
    – manufacturing on Bayer technology

    1939-1945

    Bayer takes over

    1939-1945
     
    1949
     
    1949

    Reconstruction of Polpharma after II World War. First product after the war - redistilled water in glass ampoules.

    1951

    Minister of Industry establishes Starogard Pharmaceutical Plant
    which starts producing salicylates
    and sulfonamides.

    1951
     
    1959
     
    1959

    Starogard Pharmaceutical Plant becomes a part of the Union of Pharmaceutical Industry “Polfa” and is renamed to Starogard Pharmaceutical Works “Polfa”.

    1995

    Polpharma transforms into a Joint Stock Company with 100% shares belonging to the State Treasury and returns to its old name - Pharmaceutical Works POLPHARMA S.A.

    1995
     
    2000
     
    2000

    Spectra Holding and Prokom Investments (Polish capital) buy the majority of the Company shares converting it to a private company.

    2007

    Strategic alliance with Akrikhin, major generic pharma player in the Russian market.

    2007
     
    2010
     
    2010

    Acquisition of antibiotic business of Bioton Poland together with a cephalosporin manufacturing plant in Duchnice, Poland.

    2011

    Polpharma becomes a major
    shareholder of Akrikhin, Russia

    2011
     
    2011
     
    2011

    Polpharma becomes a key partner of Chimpharm, Kazakhstan

    2012

    Polpharma becomes a major shareholder of Polfa Warsaw, Poland

    2012
     

    LOCATION

    STAROGARD GDAŃSKI, POLAND

    • 50 km from Gdańsk international Airport
    • 70 km from a major Polish seaport in Gdańsk and Gdynia
    • 11 km from a major highway




    Mapa

    Site Data

    Industrial area: 104 hectares

    • Finished Dosage Forms Manufacturing
    • API Manufacturing
    • Quality Control Labs
    • R&D Centers for FDF and API
    • Distribution and warehouses
    • Administration offices
    • Infrastructure

     

    API Polpharma
    API POLPHARMA